Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ZYDUSLIFE

ZYDUSLIFE

HealthcarePharmaceuticals & Biotechnology₹102404 cr market cap
₹1200.00 ▼ -0.17% today As of 19 Nov 2026
52-week low ₹860.6052-week high ₹1245.50

-3.5% from the 52-week high · +39.7% above the low

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat and currently employs 23,026 full-time employees. The firm is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. The company is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.

The short version. ZYDUSLIFE reported revenue of ₹7,910 crore for Sep 2026, up 29.2% from a year earlier. Net profit was ₹926 crore (down 26.4% year on year). Return on equity was 18.6% in Mar 2026. Promoter holding was 75.01% in Sep 2026, up 0.03 points over 8 quarters.

1 · The price

How has the stock traded?

ZYDUSLIFE trades 3.5% below its 52-week high and 39.7% above its 52-week low.

Change over period: —

1M+7.9%
3M+8.8%
6M+15.5%
1Y+29.5%

2 · The business

Is it growing?

Sales, year on year+29.2%

Sep 2026 revenue of ₹7,910 cr.

Profit, year on year-26.4%

Sep 2026 net profit of ₹926 cr.

Net margin11.7%

8.9 pts lower than a year earlier.

3-year growth37.0% profit

Revenue compounded at 16.7% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue79108017758768646123657465285269
Net profit9269401272104212591467731024
Net margin %11.711.716.815.220.622.31.119.4
EPS (₹)9.289.4212.6510.3612.5114.580.7210.17

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue2714823242195471723715265151021425313166
Net profit50404526386019604487213411771849
Net margin %18.619.519.711.429.414.18.314.0
EPS (₹)50.0944.9738.3619.3743.8320.8411.4918.06

3 · The quality

How well does it turn capital into profit?

Return on equity was 18.6% in Mar 2026; debt to equity is 0.43.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %18.618.919.511.2
Return on capital %19.222.020.413.4
EBITDA margin %30.630.228.519.8
Net margin %18.219.219.511.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR16.7%12.8%
Profit CAGR37.0%18.8%
Debt to equity0.43
Interest cover16.1x
Current ratio1.27

4 · The owners

Who holds it, and are they adding?

Promoter holding75.01%

Up 0.03 pts over 8 quarters.

Foreign institutions7.05%

Down 0.48 pts over 8 quarters.

Domestic institutions11.28%

Up 0.63 pts over 8 quarters.

Mutual fund schemes230

+66 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter74.9874.9974.9974.9975.075.075.0175.01+0.03
FII7.537.327.137.347.066.956.887.05-0.48
DII10.6511.0111.1310.8611.0911.211.2711.28+0.63
Public6.846.686.746.86.856.866.836.66-0.18

Mutual fund holdings · Oct 2026

230 schemes hold this stock

164 the month before.

  • quant Aggressive Hybrid Fund10.37% of NAV
  • quant Healthcare Fund10.25% of NAV
  • quant Consumption Fund8.02% of NAV
  • quant Large & Mid Cap Fund6.94% of NAV
  • quant Mid Cap Fund6.11% of NAV
  • SAMCO LARGE CAP FUND5.86% of NAV
  • quant Quantamental Fund5.02% of NAV
  • quant Multi Cap Fund4.09% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ZYDUSLIFE are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ZYDUSLIFE

What is the ZYDUSLIFE share price?

ZYDUSLIFE (ZYDUSLIFE) last closed at ₹1,200.00, down 0.17% on the day. Its 52-week range is ₹860.60 to ₹1,245.50.

What is the market cap of ZYDUSLIFE?

ZYDUSLIFE has a market capitalisation of about ₹102,404 crore.

How are ZYDUSLIFE's latest results?

ZYDUSLIFE reported revenue of ₹7,910 crore for Sep 2026, up 29.2% from a year earlier. Net profit was ₹926 crore (down 26.4% year on year). Return on equity was 18.6% in Mar 2026. Promoter holding was 75.01% in Sep 2026, up 0.03 points over 8 quarters.

Who owns ZYDUSLIFE?

As of Sep 2026, shareholding was: Promoter 75.01%, FII 7.05%, DII 11.28%, Public 6.66%.

How many mutual funds hold ZYDUSLIFE?

230 mutual fund schemes held ZYDUSLIFE in October 2026. That compares with 164 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 25 Jul 2025 · Final Dividend - Rs. 11
  • 26 Jul 2024 · Final Dividend - Rs. 3
  • 28 Jul 2023 · Final Dividend - Rs. 6
  • 28 Jul 2022 · Final Dividend - Rs. 2.5
  • 28 Jul 2021 · Final Dividend - Rs. 3.5
  • 23 Mar 2020 · Interim Dividend - Rs. 3.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.